Previous aminoglycoside use and acute kidney injury risk in non-critically ill children.

Abstract

Aminoglycosides (AG) are a group of bactericidal antibiotics with nephrotoxic effects that are commonly used in the treatment of hospitialized children. We have examined previous AG treatment as a risk factor for acute kidney injury (AKI) during current AG treatment. We performed a retrospective cohort study of children ranging in age from 1 month to 18 years who were treated with AG between October 2008 and April 2012 at Montreal's Children's Hospital. Children for whom no serum creatinine data (SCr) were available and those with baseline renal disease were excluded from the analysis. Main exposures were prior AG use (number and hours of prior treatments) and time since last AG treatment. The main outcome was AKI, defined on the basis of theKidney Disease: Improving Global Outcomes guidelines. Logistic regression was used to examine exposure-outcome associations. AG treatments episodes with Stage 1, 2, and 3 AKI, respectively, were associated with a median of 98 [interquartile range (IQR) 339], 231 (IQR 688), and 111 (IQR 505) h of prior AG treatment, respectively, versus non-AKI (median 0, IQR 54 h) (p < 0.0001). AKI episodes were associated with a mean (± standard deviation) of 1.5 ± 1.8 AG treatments in the previous 6months, versus 0.9 ± 1.6 AG treatments for non-AKI. The number of AG-treatment days during the preceding 6 months [adjusted odds ratio (adjOR) 1.04, 95% confidence interval (CI) 1.03-1.06; p < 0.001], younger age (adjOR 0.96, 95% CI 0.93-0.99; p = 0.009), admission to hematology-oncology department (adjOR 3.88, 95% CI 2.17-6.96; p < 0.001), and tobramycin use (adjOR 1.77, 95% CI 1.04-3.02; p = 0.04) were independently associated with AKI. Episodes with Stage 1 and 2 AKI were associated with fewer days since last treatment compared to non-AKI treatment (p < 0.02 and p < 0.005, respectively; Mann-Whitney test). Based on these results, priorAG treatment is a risk factor for AKI and should be considered when dosing and monitoring hospitalized children being treated with AG.